CDC advisers could reverse newborn hepatitis B vaccine recommendations

Hepatitis B vaccines given at birth have essentially eliminated the disease in kids. A vote this week could upend that ...

New research discovers dementia-linked protein's role in DNA mistakes

New Houston Methodist research has revealed that a protein associated with neurodegenerative diseases such as dementia and ...
Gut

Decoding HBV-specific adaptive immunity: from natural clearance to cure

Chronic HBV infection remains a major global health burden, with current antiviral therapies effectively suppressing viral ...
BioWorld

Bluejay way: Positive phase II data for treating hepatitis D

Bluejay Therapeutics Inc.’s lead compound, the fully human monoclonal antibody brelovitug (BJT-778), produced positive virologic response data in the company’s phase II study of chronic hepatitis D ...
MedPage Today

Investigational Combination Shows Promise in Chronic Hepatitis D

WASHINGTON -- An investigational dual therapy appeared to show antiviral activity in patients with chronic hepatitis D virus (HDV) infection, according to the phase II SOLSTICE trial. At week 24, the ...
The New England Journal of Medicine

A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D

Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen (HBsAg). Their efficacy and safety in the treatment of chronic hepatitis D ...
The Weekly Times

Govt called to act on hepatitis death rate

A PEAK body representing hepatitis sufferers says governments need to act to prevent a "tidal wave" of life-threatening liver disease. HEPATITIS Australia, which represents the half a million ...